SavedAdd your journal

Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2014 / Cilt: 23 - Sayı: 1

Yeni tanı almış yetişkin hipertansif hastalarda, amlodipin ve valsartan tedavisinin kemik yapım-yıkım belirteçleri ve OPG/RANKL/RANK sistemi üzerine etkisi; hangisi daha faydalı?

Influences of treatment with amlodipine and valsartan on bone turnover markers and OPG/RANKL/RANK system in newly diagnosed hypertensive adults; which is more beneficial?

İlker TAŞÇI
Ergun BOZOĞLU
Murat KARAMAN
Nuri KARADURMUŞ
Seyid Ahmet AY
Mustafa DİNÇ
Umut SEFER
Hüseyin DORUK
Serkan TAPAN
Mustafa ÇAKAR
Mehmet İlkin NAHARCI
Pages
40–45
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Amlodipine reduced sRANKL levels and sRANKL/OPG ratio more than valsartan, and this decrease was statistically significant (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We aimed to investigate the effects of treatment with amlodipine and valsartan, on markers of bone remodeling in newly diagnosed hypertensive adults.
📊
Key Findings & Data:Forty-three subjects with newly diagnosed were included in the study.
💡
Conclusion & Impact:Amlodipine reduced sRANKL levels and sRANKL/OPG ratio more than valsartan, and this decrease was statistically significant (p
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

We aimed to investigate the effects of treatment with amlodipine and valsartan, on markers of bone remodeling in newly diagnosed hypertensive adults. Forty-three subjects with newly diagnosed were included in the study. Patients were also randomly divided into two groups, and each group received monotherapy with amlodipine or valsartan. Blood levels of bone turnover markers and osteoprotegerin (OPG) / receptor activator of nuclear factor-κB ligand (RANKL) / RANK system were measured. Amlodipine reduced sRANKL levels and sRANKL/OPG ratio more than valsartan, and this decrease was statistically significant (p

Özet

Bu çalışmada amacımız; yeni tanı almış, yetişkin hipertansif hastalarda Amlodipin ve Valsartan tedavisinin kemik yeniden şekillendirilmesi (remodeling) üzerine olan etkisini araştırmaktır. Çalışmaya daha önce tedavi almamış 43 yeni tanılı hasta alındı.Hastalar rastgele iki gruba ayrıldı. Her bir gruba monoterapi şeklinde Amlodipin ve Valsartan verildi. Kemik yapım-yıkım belirteçleri yanında osteoprotegerin (OPG) / nükleer faktör kappa-B reseptör aktivatörü ve ligand(sRANKL) / RANK sistemi çalışıldı. Amlodipin kolunda sRANKL düzeyinin ve sRANKL/OPG oranınının valsartandan daha fazla azaldığı ve bunun istatistiki açıdan anlamlı olduğu görüldü (p

🔖

Cite This Article

TAŞÇI, İ., BOZOĞLU, E., KARAMAN, M., KARADURMUŞ, N., AY, S. A., DİNÇ, M., SEFER, U., DORUK, H., TAPAN, S., ÇAKAR, M., NAHARCI, M. İ. (2022). Yeni tanı almış yetişkin hipertansif hastalarda, amlodipin ve valsartan tedavisinin kemik yapım-yıkım belirteçleri ve OPG/RANKL/RANK sistemi üzerine etkisi; hangisi daha faydalı?. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 23 - Sayı: 1, 40–45. https://ajindex.com/articles/636295

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Caudarella R, Vescini F, Rizzoli E, Francucci CM: Salt intake, hypertension, and osteoporosis. J Endocrinol Invest 2009; 32: 15-20
  2. Resnick LM, Laragh JH, Sealey JE, Alderman MH: Divalent cations in essential hypertension: Relations between serum ionized calcium, magnesium, and plasma renin activity. N Engl J Med 1983; 309: 888-891
  3. Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB: Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J Nephrol 2000; 13: 169-177
  4. Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA: High blood pressure and bone-mineral loss in elderly white women: A prospective study. Study of Osteoporotic Fractures Research Group. Lancet 1999; 354: 971-975
  5. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR: Use of beta- blockers and risk of fractures. JAMA 2004; 292: 1326-1332
  6. Rejnmark L, Vestergaard P, Mosekilde L: Treatment with beta- blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: A nationwide case-control study. J Hypertens 2006; 24: 581-589
  7. Nishiya Y, Sugimoto S: Effects of various antihypertensive drugs on the function of osteoblast. Biol Pharm Bull 2001; 24(6): 628-633
  8. Ritchie CK, Maercklein PB, Fitzpatrick LA: Direct effect of calcium channel antagonists on osteoclast function: Alterations in bone resorption and intracellular calcium concentrations. Endocrinology 1994; 135(3): 996-1003
  9. Halici Z, Borekci B, Ozdemir Y, Cadirci E, Suleyman H: Protective effects of amlodipine and lacidipine on ovariectomy-induced bone loss in rats. Eur J Pharmacol 2008; 579(1-3): 241-245
  10. Gradosova I, Zivna H, Palicka V, Hubena S, Svejkovska K, Zivny P: Protective effect of amlodipine on rat bone tissue after orchidectomy. Pharmacology 2012; 89 (1-2): 37-43
  11. Ruilope LM, Segura J: The importance of integrated risk management when treating patients with hypertension: Benefits of angiotensin II receptor antagonist therapy. Clin Exp Hypertens 2008; 30: 397-414 Broulík PD, Tesar V, Zima T, Jirsa M: Impact of antihypertensive therapy on the skeleton: Effects of enalapril and AT1 receptor antagonist losartan in female rats. Physiol Res 2001; 50: 353-358
  12. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R: Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008; 22: 2465-2475
  13. Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T, Nakashima K, Inagami T, Ezura Y, Noda M: Angiotensin